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Technological advancements in the molecular characterization of cancers have enabled researchers to identify an
increasing number of key molecular drivers of cancer progression. These discoveries have led to multiple novel
anticancer therapeutics, and clinical benefit in selected patient populations. Despite this, the identification of
clinically relevant predictive biomarkers of response continues to lag behind. In this review, we discuss strategies for
the molecular characterization of cancers and the importance of biomarkers for the development of novel
antitumor therapeutics. We also review critical successes and failures in oncology, and detail the lessons learnt,
which may aid in the acceleration of anticancer drug development and biomarker discovery.
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The process of novel drug development from first-in-
human studies to registration phase III clinical trials is
associated with an unacceptably high attrition rate [1].
Reversing such alarming trends requires rational patient
and drug selection to achieve precision medicine in clinical
studies [2]. The recognition that intracellular processes
drive multiple hallmarks of cancer, including angiogenesis,
apoptosis, invasion and metastasis, has highlighted the po-
tential to affect oncogenesis and cancer progression by ma-
nipulating these critical processes at a molecular level [3].
Sequencing the cancer genome is a vital component to un-
derstanding the molecular basis of cancer; for example,
tumor sequencing undertaken at an individual patient level
can be utilized to identify specific molecular dependencies
and vulnerabilities that may be targeted with antitumor
therapies. The BCR-ABL translocation product in chronic
myelogenous leukemia (CML), the anaplastic lymphoma
kinase (ALK) mutation in lung cancer and the BRAF
V600E mutation in melanoma are prime examples of
specific subsets of cancers that are exquisitely sensitive
to rationally selected molecularly targeted antitumor
agents [4-6].* Correspondence: timothy.yap@icr.ac.uk
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unless otherwise stated.The Pharmacologic Audit Trail (PhAT) is a drug de-
velopment framework that can be used to link bio-
markers for rational decision-making in early phase
clinical trials of novel antitumor therapeutics [7,8]. The
PhAT incorporates a step-wise process, starting with the
identification of patients who possess a tumor associated
with a specific predictive biomarker that may predict for
antitumor response to a particular therapy. While on
treatment, pharmacokinetic (PK) profiling and measure-
ment of target and pathway modulation with pharmaco-
dynamic (PD) biomarkers can then be used to ensure
active drug exposures are achieved with adequate target
engagement [9]. Intermediate endpoint biomarkers may
also be used to assess for early signals of clinical re-
sponse, with the assessment of various biomarkers indi-
cative of resistance mechanisms on disease progression
where appropriate [10,11]. In recent years, a number of
molecularly targeted agents have been developed using
such strategies that illustrate the importance of a ra-
tional approach to drug development. We will discuss
strategies for the molecular characterization of patients,
and the importance of utilizing different biomarkers in
the multistep drug development process. Finally, we will
detail key examples that have transformed the landscape
of anti-cancer therapeutics, as well as the efforts made
in associated biomarker development relevant to these
examples.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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In the early 1990s, the first human genome sequenced
cost more than $2 billion and took a decade to complete
[12]. Novel technologies have seen both processing times
and costs fall significantly, such that we are now able to
sequence the entire genome in greater detail with im-
proved precision and accuracy [13]. These advances now
need to be exploited so as to accelerate oncological drug
development and to optimize patient benefit. Such tech-
nologies need to be utilized to identify cancers that are
more likely to respond to antitumor molecularly targeted
agents by exploiting specific dependencies and vulner-
abilities through the use of rational clinical trials [14].
Such an approach has the potential to reduce the num-
ber and size of large and costly “one-size-fits-all” Phase
III trials, as well as the high level of late-phase drug attri-
tion. A refined understanding of underlying tumor biology
would ultimately lead to such a discovery through the inter-
rogation of cancer genetic blueprints, for example through
DNA sequencing. Commonly employed methods of DNA
sequencing may involve genome-wide single nucleotide
polymorphism (SNP) microarrays, detection of structural
and chromosomal variations, gene-specific Sanger sequen-
cing, and whole genome (WGS) or whole exome sequen-
cing (WES) [15].
SNP Genotyping
Measuring genetic variation in single nucleotides (SNP
genotyping) may potentially identify mutations in genes
that have functional consequences. The Affymetrix and
Illumina platforms are examples of genome wide SNP
genotyping that use hybridization and enzyme-based
techniques [16]. Another example is the Sequenom
MassARRAY platform, which uses mass spectrometry
to detect the mass of the SNP allele extension, rather
than a fluorescing molecule, and may not be as useful
for whole genome scanning [17]. Overall, SNP genotyp-
ing provides a rapid and relatively cost-efficient method
to assess the cancer genome for a number of known
genetic mutations [18]. One of the major limitations of
this technology is the inability to identify non-SNP mu-
tations of interest.
Next generation sequencing
First generation sequencing (Sanger sequencing) is the
original form of WGS DNA sequencing, and allows for
long read lengths and high accuracy. However, it may be
costly and is low-throughput. Therefore, despite improve-
ments in the process, it has largely been supplanted by
next-generation sequencing (NGS) [18]. NGS with WES
or WGS has gained favor because it uses massively parallel
sequencing assays to interrogate DNA coding regions or
the entire euchromatic genome, respectively, resulting
in higher throughput. NGS generally involves DNAfragmentation, clonal amplification using polymerase chain
reaction (PCR) and sequencing via cyclic enzyme-driven
identification of sequential nucleotides, before reconstruc-
tion of the original sample is performed using software that
aligns overlapping reads from each fragment [18-20].
Targeted sequencing is a strategy that has been employed
to improve time to acquisition of results and reduction
of costs. This process typically involves prior identifica-
tion of specific genes of interest, followed by targeted
exon sequencing using the relevant DNA arrays [21]. An-
other method, targeted comparative genomic hybridization
(CGH), may be used to identify specific gene deletions and
duplications [22].
Despite these advancements, there continue to be limi-
tations of NGS rooted in the methodology. Most NGS
methods involve amplification of DNA strands, followed
by the addition of labeled-bases that can be incorporated
into the newly forming fragment by DNA polymerase.
The DNA base solvent is then washed out and imaging
is used to identify the base incorporated. Repetition of
this process is limited by a number of issues, including
short read-length which can result in lower accuracy,
complex sample preparation, need for amplification,
prolonged duration to results, significant data storage,
costs and interpretation requirements [18]. Novel third
generation technologies, such as PacBio RS and Ion
Torrent PGM, have sought to improve on these limita-
tions [23]. Strategies such as single molecule real-time
sequencing (SMRTS) developed by Pacific Biosciences dir-
ectly observes a single molecule of DNA polymerase as it
synthesizes DNA, minimizing the need for reagents, elim-
inating time-consuming washing and scanning steps, and
accelerating time to results. Tunneling and transmission
electron microscopy directly images the DNA and chem-
ically identifies atoms in nucleotide molecules. This
method is currently in development, and promises to
increase read lengths at low costs. Another method of
third generation sequencing involves DNA sequencing
using nanopores. This technology relies on membranes
that allow the passage of DNA molecules or nucleotides
through holes, and detects their passage by changes in
electrical current or optical signals [23].
Biomarkers for successful drug development
Historically, clinical trials in drug development have
employed a toxicity-driven approach to reach a prede-
fined ‘toxicity ceiling’, maximizing drug exposure with
the assumption that this will also maximize antitumor
effects. As cancer medicine becomes more sophisticated,
the development of novel molecularly targeted agents
has required researchers to refine this approach for a
number of reasons. Firstly, targeted agents are designed
to block a specific molecule or intracellular pathway and
therefore often have a limited toxicity profile relative to
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apies never reach a ‘toxicity ceiling’ or maximum tolerated
dose (MTD) in classically designed dose-escalation trials. A
greater understanding of the intracellular pathways integral
to cancer cells will also facilitate the determination of PD
effects by measuring the activity of downstream markers
and alternate pathways. This allows for the potential to
tailor dose and dosing schedule to PD drug effects, rather
than toxicities. Interest in developing methods to evaluate
treatment efficacy earlier in the treatment course has
fueled the investigation of novel biomarker assays as pos-
sible intermediate endpoint biomarkers of response.
Promising novel biomarkers should be systematically
assessed, both retrospectively and prospectively [24]. Ultim-
ately, we foresee the goal of developing multiple biomarkers
(i.e. predictive, pharmacodynamic, pharmacokinetic, phar-
macogenomic and intermediate endpoint biomarkers) for
incorporation within intelligent, hypothesis-driven early
phase clinical trials to combine with robust outcome data.
The discovery and evaluation of any novel biomarkers
will ideally be certified to Clinical Laboratory Improve-
ment Amendments (CLIA) and Good Clinical Labora-
tory Practice (GCLP) standards, so as to ensure
accuracy and reproducibility of laboratory procedures.
In this section, we highlight and discuss the critical bio-
markers that will be vital for the successful develop-
ment of novel molecularly targeted therapeutics.
Predictive biomarkers
Predictive biomarkers indicate the likelihood of response
to a specific antitumor therapy. Such assays should be
scientifically sound, have preclinically validated method-
ologies, and have been clinically proven in prospective
randomised trials to robustly and reproducibly predict
antitumor efficacy in the applied patient population [9].
Predictive biomarkers include both tumor-specific and
surrogate biomarkers, and are crucial to accelerating the
drug development process. For example, ERBB2 (HER2)
is a cellular transmembrane tyrosine kinase encoded by
the ERBB2 gene. HER2 overexpression or amplification
in breast cancers is a useful biomarker that has been
critical for the identification of patients who are likely to
respond to HER2 targeting drugs, thereby enabling the
development of trastuzumab [25,26], pertuzumab [27],
trastuzumab-DM1 [28,29] and lapatinib [30]. Another
well-established predictive biomarker is the oncogenic
BCR-ABL gene fusion, which predicts for antitumor re-
sponses to the tyrosine kinase inhibitor imatinib in
chronic myelogenous leukemia [31]. More recently, bio-
markers that have been used to enrich or predict for sensi-
tivity to a targeted agent include BRCA1 and BRCA2
mutations to the PARP inhibitor olaparib [32-35]; EML4-
ALK fusions to the ALK/MET inhibitor crizotinib [5];
V600E BRAFmutation to the BRAF inhibitor vemurafenib[36]; EGFR wild-type metastatic colorectal cancer to the
EGFR-targeted antibodies panitumumab [37] and cetuxi-
mab [38]; and EGFR mutant advanced non-small cell lung
cancer (NSCLC) to the small molecule inhibitors gefitinib
[39] and erlotinib [40,41].
The term ‘enrichment biomarker’ has been used to
describe biomarkers with strong scientific rationale and
preclinical evidence for antitumor response, but which
lack clinical validation [7]. Such enrichment biomarkers
currently in clinical trials may of course be clinically
qualified and become predictive biomarkers in the fu-
ture. Examples include PTEN loss or PIK3CA mutations
for PI3K-Akt-mTOR pathway inhibitors (NCT01458067;
NCT01449370); RAS mutations for the combination of
MAPK and PI3K pathway inhibitors (NCT01449058) and
IGF mutations with IGF-1R antibodies (NCT01403974;
NCT01562899). Different biomarker panels, such as the
TruSeq Amplicon – Cancer Panel (TSACP), have been
developed to facilitate the identification of relevant bio-
markers (i.e. genetic mutations) for research, and can
be a useful point-of-care test [42].
Pharmacodynamics, pharmacokinetics and
pharmacogenomics
The use of molecularly targeted agents has necessitated
PD biomarkers, which indicate drug effects on the target,
pathway and downstream cellular processes [7,43]. Pre-
clinical studies to establish and evaluate PD biomarkers
are therefore essential for the development of novel anti-
tumor therapeutics. Similarly, PK profiling is crucial to en-
sure active drug exposures and to establish PK-PD drug
profiles and toxicity relationships [9]. This information
can then be used to direct Phase I studies by providing PK
and PD thresholds to target. Use of fresh tumor tissue still
remains the gold standard for biomarker evaluation; how-
ever obtaining normal tissue such as platelet-rich plasma,
peripheral blood mononuclear cells, hair follicles and skin
is relative less invasive and can be sampled serially,
thereby minimizing inter- and intra-patient variability
[44]. PK and PD variability between patients following
fixed doses of targeted therapies may also be affected by
individual pharmacogenomic factors. Such genetic vari-
ability between hosts may impact the expression or func-
tion of proteins that metabolize the drug or may affect the
drug target itself, thereby affecting treatment efficacy and
toxicity. The current clinical practice is to dose adjust for
patients who experience unacceptable toxicities; however,
such practice will mean that a substantial proportion of
patients are inevitably undertreated unless their dose is
escalated.
Intermediate endpoint biomarkers
Intermediate endpoint (surrogate) biomarkers indicate
treatment efficacy at an earlier time point than the
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tute for the clinical primary endpoint [45]. Established
surrogate biomarkers can therefore accelerate drug ap-
proval, facilitate earlier decisions about treatment efficacy
and mitigate costs and morbidity related to treatment.
Numerous biomarkers have been studied for surrogacy,
however trials evaluating their validity are often poorly re-
producible, inaccurate, inconsistently applied or only
loosely associated with survival [46,47]. Changes in tumor
markers, such as PSA and CA125, continue to be used as
surrogate biomarkers, however the data remains contro-
versial as to how predictive they are for survival [46,47].
Progression-free survival (PFS) is also often used as a sur-
rogate for overall survival, however, this remains contro-
versial in many cancers, particularly in the era of targeted
therapies [48-50]. More recently, circulating tumor cells
(CTCs) have been evaluated as a surrogate biomarker in a
number of cancers, including castration-resistant prostate
cancer (CRPC), lung, breast and colon cancer [51-59]. Cir-
culating plasma DNA also appears to have promising util-
ity as a biomarker, demonstrating correlation with tumor
behaviour and changes in cancer burden in malignancies
such as breast, lung, gastrointestinal stromal tumors and
ovarian cancers [60-64]. Other studies have documented
detectable levels of circulating plasma DNA in pancreatic,
colorectal, bladder, gastroesophageal, melanoma, hepato-
cellular, and head and neck cancers [65]. Ultimately, better
preclinical models may be helpful in deciphering the rele-
vant molecular mechanisms of response and resistance.
Patient-derived tumor xenografts (PDX) and genetically-
engineered mouse models (GEMM) are two model sys-
tems that can be used to study surrogate markers in the
laboratory [66]. Recently, further progress has been
made in the use of PDX models for developing
biomarker-driven hypotheses that can be tested in the
clinic to identify patients that may benefit from a thera-
peutic intervention [67].
Proteomics and metabolomics
The cancer proteome (i.e. the complete set of proteins
expressed by the cancer) and the cancer metabolome
(i.e. the entire set of small molecule metabolites produced
by the cancer) may also be informative [68]. Methods such
as mass spectrometry, electrophoresis and protein micro-
arrays can be used to profile metabolomic and proteomic
signatures, and identify molecules that are differentially
expressed in certain cancers [68-71]. Mass spectrometry
can also be used for ‘metabolic phenotyping’ by mapping
the interconnected networks of biochemical pathways,
which may lead to the identification of candidate bio-
markers [72]. Low abundance proteins, for example in
a single cell type, can be evaluated using deep proteo-
mics methods, such as liquid chromatography and
high-resolution mass spectrometry [73].Modern functional imaging biomarkers
Well-established imaging modalities such as computed
tomography (CT) and magnetic resonance imaging (MRI)
are important techniques used to structurally evaluate
tumor growth and drug efficacy in clinical practice. How-
ever, they are not able to functionally assess lesions, nor
do they address any specific molecular processes within
the tumor. The availability of novel functional imaging
probes may enable the assessment and monitoring of mo-
lecular pathways involved in a range of cellular processes,
including angiogenesis, metabolism, cell proliferation, in-
filtration, metastasis and apoptosis [74]. Functional im-
aging techniques such as dynamic contrast-enhanced MRI
(DCE MRI), diffusion-weighted imaging MRI (DWI MRI),
18 F-fluorodeoxyglucose positron emission tomography
(FDG-PET), and magnetic resonance spectroscopy (MRS)
are frequently employed modalities that can measure the
relevant cancer-specific molecules and signaling pathways
[43,75]. For instance, PET tracers can be used quantita-
tively to measure markers of cellular proliferation, cell
hypoxia and apoptosis [76]. Dynamic image acquisition
and compartmental modelling can also be used with PET/
CT to assess tumor perfusion, tracer extraction and tissue
metabolism [77]. In addition, new methods of MRI have
enabled dynamic, functional and metabolic assessments of
changes in the tumor vascular network with perfusion or
permeability imaging, such as dynamic contrast-enhanced
(DCE) MRI, or the tumor microenvironment with diffusion-
weighted imaging (DWI) [78-80]. Such methods allow
rapid non-invasive evaluation of tumor response and
mechanisms of drug action. Nevertheless, issues including
high costs and variability in techniques between institu-
tions and MRI platforms have limited the routine applica-
tion of functional MRI readouts as a valid biomarker [76].
Lessons learnt from successes in drug development
There have been several examples of successful monoclo-
nal antibody and small molecule drug development
programs in the field of oncology over the past decade
(Table 1). To date, multiple targeted therapies have been
approved by the US FDA, with many more currently in
different phases of clinical trial testing [81]. In this section,
we detail key examples that have paved the way for the de-
velopment of other novel antitumor agents, and discuss
efforts and progress made in biomarker discovery for such
drugs. Figure 1 illustrates a potential patient pathway in
the clinic for rational biomarker and clinical drug develop-
ment. Figure 2 highlights key pathways that are targeted
by novel anti-cancer therapeutics, as discussed below.
Monoclonal antibodies
Angiogenesis inhibitors
Bevacizumab is a humanized monoclonal antibody against
vascular endothelial growth factor A (VEGF-A), which is a
Table 1 Identified biomarkers and their relevant drugs in selected cancers*
Biomarker Drug Drug action Cancer type (Survival benefit)
ALK Ceritinib Tyrosine kinase inhibitor of ALK Lung cancer
Crizotinib Tyrosine kinase inhibitor of ALK Lung cancer
BRAF (V600E) Dabrafenib Inhibits B-RAF protein Melanoma
Trametinib Inhibits MEK1 and MEK2 growth factor-mediated signaling Melanoma
Vemurafenib Small molecule inhibitor of BRAF (V600E) kinase Melanoma
CTLA-4 Ipilimumab Monoclonal antibody directed against CTLA-4, enhancing
T-cell activation
Melanoma
EGFR Afatinib Irreversibly inhibits EGFR, HER2, HER4, mutant EGFR (exon 19, 21) Lung cancer
Cetuximab Recombinant, chimeric, monoclonal antibody directed
against EGFR
Colorectal cancer, SCCHN**
Erlotinib Reversible tyrosine kinase inhibitor of EGFR Lung cancer, Pancreatic cancer
Gefinitib Tyrosine kinase inhibitor of EGFR Lung cancer
Panitumumab Humanized monoclonal antibody directed against EGFR Colorectal cancer
HER2 Lapatinib Reversible tyrosine kinase inhibitor of EGFR, HER2 Breast cancer
Pertuzumab Recombinant, humanized, monoclonal antibody preventing
HER2 dimerization
Breast cancer
Trastuzumab Recombinant, humanized, monoclonal antibody directed
against HER2
Breast cancer, Gastric cancer
Trastuzumab-mertansine
(T-DM1)
Antibody-drug conjugate consisting of trastuzumab
conjugated to DM1, which binds tubulin and disrupts
microtubule assembly/disassembly dynamics
Breast cancer
KIT Imatinib Tyrosine kinase inhibitor of c-kit GIST***
Sunitinib Tyrosine kinase inhibitor of VEGFR2, PDGFRb and c-KIT GIST***
MEK Trametinib MEK1/2 inhibitor Melanoma
*Solid tumor malignancies.
**SCCHN = squamous cell cancers of the head and neck.
***GIST = gastrointestinal stromal tumors.
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in tumors [82]. It was the first anti-angiogenic drug
approved for the treatment of patients with advanced
colorectal cancer [83]. However, despite its broad
clinical activity, no definitive predictive biomarkers of
antitumor response have been identified, despite mul-
tiple large high profile clinical studies in this area
[84]. For example, Cameron and co-workers under-
took a phase III trial assessing the role of bevacizu-
mab in patients with resected triple-negative breast
cancer [85]. In this study, 2591 patients were randomly
allocated to four or more cycles of anthracycline-based
or taxane-based chemotherapy with or without beva-
cizumab. The primary endpoint of progression-free
survival was however not met and importantly grade 3
or worse toxicity was more common with the bevaci-
zumab arm [85,86].
In addition, bevacizumab is the only antiangiogenic drug
approved by the FDA for the first-line management of
NSCLC and HER2-negative breast cancer, and second-
line treatment of glioblastoma, and metastatic renal cell
carcinoma [87]. Bevacizumab efficacy for advanced lungcancer was recently demonstrated in a number of clinical
trials, which demonstrated improved OS and PFS, albeit
only by a few months [88-90].
Recently, Lambrechts and colleagues investigated novel
promising biomarkers of response for bevacizumab treat-
ment [91]. While VEGF-A isoforms and modified expres-
sion of VEGFRs (VEGFR1 and NRP1) appeared to be
good candidates, these biomarkers demonstrated a lack of
consistency across studies in multiple cancer types on
retrospective analysis [91]. The ongoing MERIDIAN trial
in metastatic breast tumors will evaluate the impact of
bevacizumab treatment in patients stratified by plasma
short VEGFA isoforms (NCT01663727).
Epithelial growth factor receptor inhibitors
The EGFR pathway is another commonly targeted signal-
ing cascade in antibody therapeutics. Cetuximab is an
IgG1 anti-EGFR antibody targeted against the extracellu-
lar domain of EGFR and is approved for use in advanced
colorectal cancer and squamous cell carcinoma of the
head and neck (SCCHN) [38,92-94]. In comparison, pani-
tumumab is a fully humanized IgG2 monoclonal antibody,
Figure 1 Translation of sequencing into Clinical Oncology & Research. Patients start with informed consent to access their archived tumor
sample. When applicable, circulating tumor cells and plasma DNA are sampled; as well as accessible fresh tumor. Tumor DNA is then purified and
sequenced, and the results are presented at a tumor board of experts, where the patient is then allocated to an appropriate trial based on the
results. Fresh tumor can also be grafted into mice to determine if a theraphy is effective, before giving to the patient. Tumor resampling after
progression on theraphy is essential to identifying the mechanism of resistance and a new treatment strategy.
Figure 2 Molecular pathways in cancer progression. This figure identifies some of the common pathways involved in cancer cell growth and
proliferation. Proteins such as Receptor Tyrosine Kinases (RTKs) (i.e. EGFR, HER2, VEGFR, PDGFR, IGFR, KIT) PI3K, AKT, RAF, MEK, and SHH represent
some of the drug targets in precision medicine.
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static colorectal cancer [95,96].
It is now clear that KRAS mutations are a negative
predictive indicator of response to anti-EGFR therapy in
view of downstream pathway activation [97-99]. How-
ever, the use of EGFR expression testing is still contro-
versial since the large phase III CRYSTAL trial showed
no correlation between treatment response and immu-
nohistochemical EGFR determination [38].
In advanced SCCHN, although a survival advantage was
demonstrated with cetuximab plus concurrent chemo-
therapy or radiotherapy, to date, no predictive biomarkers
of response have yet been identified [94]. Vermorken and
co-workers recently published the SPECTRUM trial results,
where chemotherapy plus panitumumab were compared to
chemotherapy alone in patients with relapsed SCCHN
[100]. A subgroup analysis revealed that p16-negative
tumors treated with anti-EGFR therapy presented a sig-
nificantly higher survival benefit compared to p16-positive
tumors. Despite this being a retrospective subgroup ana-
lysis, p16 status appears to be a relevant biomarker
for patients with SCCHN, and should be explored
prospectively in the future [101].
Human epidermal growth factor receptor 2 inhibitors
The development of anti-HER2 targeting agents has dra-
matically altered the management of HER2-positive
breast cancer and is one of the first successes of molecu-
larly targeted therapies in oncology. Currently, three
antibodies are approved for the treatment of HER2-
positive breast cancer. These include trastuzumab, a
monoclonal IgG1-class humanized murine antibody di-
rected against HER2; pertuzumab, a monoclonal IgG1-
class antibody that inhibits the dimerization of HER2
with other HER receptors; and trastuzumab emtansine
(T-DM1), an antibody drug conjugate [102].
Well-recognized predictive biomarkers of response to
anti-HER2 therapy are HER2 overexpression (3+) measured
by standardized immunohistochemistry (IHC) methods or
gene amplification demonstrated by fluorescent in situ
hybridization (FISH) [103,104]. In the HER2-positive popu-
lation, trastuzumab has moderate monotherapy antitumor
effects. However, such efficacy is enhanced in combination
with conventional chemotherapy, achieving a higher rate of
objective responses (50% vs. 32%, P < 0.001), longer dur-
ation of response (median 9.1 vs. 6.1 months; P < 0.001)
and longer survival (median survival 25.1 vs. 20.3 months;
P = 0.01) [26,105,106].
Compared to trastuzumab, pertuzumab is a monoclo-
nal antibody that sterically blocks the dimerization of
HER2 with HER1, 3 and 4 and binds to a different HER2
epitope [107], resulting in synergistic antitumor effects
when combined with trastuzumab. Pertuzumab treatment
was approved for use in combination with trastuzumaband standard chemotherapy in HER2-positive metastatic
breast cancer after showing significantly prolonged
progression-free survival (18.5 vs 12.4 months; P = 0,001),
importantly with no increase in cardiac toxic effects [108].
In the adjuvant setting, the addition of trastuzumab to cyto-
toxic chemotherapy resulted in a remarkable 50% reduction
in disease recurrence in a preselected HER2+ breast cancer
patient population [109,110].
A retrospective study published by Paik and colleagues
[111] showed that HER2-positive patients could also
benefit from adjuvant trastuzumab. They identified 174
patients from the NSABP B31 study, who lacked HER2
gene amplification despite being originally reported as
HER2-positive. Surprisingly, analysis of outcome data re-
vealed that these HER2-positive patients benefited as
much from adjuvant trastuzumab as did patients whose
tumors displayed HER2 gene amplification. These find-
ings are now being studied prospectively in a random-
ized phase III trial (NSABP B47; NCT01275677).
Antibody-drug conjugates
The ability to deliver cytotoxic chemotherapeutic agents
directly to cancer cells with targeted conjugates has been
an area of interest for some time, although its develop-
ment has been technically challenging to develop until
recent times. T-DM1 is an antibody-drug conjugate con-
sisting of trastuzumab (T) linked to the small molecule
cytotoxic payload mertansine (DM1) [112]. T-DM1 was
recently approved for the treatment of patients with
HER2-positive metastatic breast cancer that has pro-
gressed on prior trastuzumab and taxane chemotherapy
[113]. This followed the EMILIA phase III trial, which
showed that T-DM1 produced a high percentage of re-
sponses and significantly improved PFS and OS com-
pared to standard therapies for advanced HER2-positive
breast cancers. Ongoing phase III trials (MARIANNE
and THERESA) are testing this drug in different settings
within the breast cancer population. (NCT01120184 and
NCT01419197).
Recently, Phillips and co-workers [114] explored, for
the first time, the dual targeting of HER2-positive cancer
with TDM1 and Pertuzumab. They explored this dual
combination initially in cultured tumor cells, followed
by mouse xenografts and finally humans in a single-arm
phase Ib/II study. This combination showed an encour-
aging safety and tolerability profile with preliminary evi-
dence of efficacy. Interestingly, investigators observed
that the presence of the HER3 ligand, heregulin (NRG-
1β), reduced the cytotoxic activity of T-DM1 in vitro;
and that such effects were reversed by the addition of
pertuzumab. This indicates a potential resistance mech-
anism to HER2-targeted therapies.
In hematological cancers, the antibody drug conjugate
Brentuximab-vedotin has already been approved for
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large cell lymphoma, and other similar compounds are
also currently in development[115].
Small molecule inhibitors
Small molecule angiogenesis inhibitors
Sunitinib, pazopanib and sorafenib are all multikinase in-
hibitors that block angiongenesis targets (among others)
and have gained FDA-approval in the last five years for
renal cell carcinoma (RCC) and hepatocellular carcinoma
(HCC). Although there are no validated biomarkers for
targeted therapies in advanced RCC or HCC, different
groups have undertaken retrospective studies on sunitinib,
pazopanib, and sorafenib for potential biomarkers in order
to understand the interpatient variability in clinical benefit
[116-120]. Previous studies in metastatic RCC have dem-
onstrated a potential correlation between baseline soluble
protein levels and efficacy for sunitinib [116], and sorafe-
nib [121]. In addition, genetic variability, such as germline
single-nucleotide polymorphisms (SNPs) in VEGF-related
genes (e.g.VEGF-A and VEGFR3), has been investigated
as a potential predictive biomarker for such antiangiogenic
agents [116,121].
EGFR inhibitors
The approval of tyrosine kinase inhibitors (TKIs) such as
erlotinib and gefitinib was a key milestone for the treat-
ment of NSCLC, by presenting a model for targeted ther-
apy development and genetic profiling of this disease.
Retrospective analysis and subsequent prospective
clinical trials have demonstrated that EGFR mutant lung
adenocarcinoma benefits from anti-EGFR therapy, al-
though some controversy still exists regarding how best
to select these patients. Two recent studies reviewed
published data regarding this topic; Lee and colleagues
in their meta-analysis concluded that EGFR mutations
are a predictive biomarker of PFS benefit to anti-EGFR
TKIs; Goss and co-workers confirmed this conclusion,
and also suggested that an activating mutation predicts a
greater likelihood of antitumor response and that there
are a proportion of EGFR wild-type patients with
NSCLC who will still gain some benefit from this ther-
apy [122,123].
Second generation EGFR TKIs including afatinib and
dacomitinib, bind EGFR irreversibly [124,125]. In preclin-
ical studies, these drugs overcome resistance via T790M
mutation (threonine to methionine at the 790 locus, the
most common resistance mechanism), however the con-
centration required to overcome T790M activity is not
achievable in patients [126,127] due to dose-limiting
toxicity related to non-selective inhibition of wild-type
EGFR [128]. As a result, third generation EGFR TKIs
such as WZ4002 [129], CO1686 [130], AZD9291 [131],
and HM61713 [132] are currently in development, andhave been designed to target T790M and EGFR TKI-
sensitizing mutations more selectively than wild-type
EGFR [131-134].
A range of strategies combining TKIs with other ther-
apies have recently been explored [135]. Despite favor-
able preclinical data suggesting an increase in efficacy by
combining dual anti-EGFR blockade (e.g. using a com-
bination of anti-EGFR monoclonal antibody and a small
molecule inhibitor), clinical results were disappointing
[136]. In contrast to patient benefit observed with inhi-
biting the EGFR pathway with cetuximab in conjunction
with cytotoxic chemotherapy in gastrointestinal malig-
nancies, gefitinib and erlotinib showed no clinical benefit
and an increase of drug-related toxicities when com-
bined with conventional chemotherapy agents in lung
cancer [137,138].
ALK inhibitors
The 4-year period from the identification of the onco-
genic ALK gene rearrangement (ALK-positive) in NSCLC
to crizotinib approval was incredibly rapid, and an excel-
lent example of hypothesis-testing, biomarker-driven drug
development [139]. Impressive results from phase I and II
trials led to FDA approval of the ALK inhibitor crizotinib
in ALK-translocated NSCLC in 2011 [5,140].
Patients with ALK-positive lung cancer comprise only
4-5% of those with NSCLC; however, lung cancer is a
highly prevalent disease, and therefore ALK-driven tumors
represent a relatively large target population when com-
pared to rare tumors. Most tumors develop resistance to
crizotinib therapy after one to two years of treatment, and
two studies involving a small series of crizotinib-resistant
patients have recently been published [141,142].
In these studies, secondary ALK mutations were the
most common drug-resistance mechanism, present in
up to one third of the target population, predominantly
affecting the tyrosine kinase domain (L1196M). ALK
amplifications were also described in the presence or ab-
sence of ALK mutations. Other mechanisms of resistance
proposed include the development of EGFR, KIT and KRAS
gene aberrations as bypass pathways mediating crizotinib
resistance [6,143-146].
BRAF and MEK inhibitors
In 2011, vemurafenib was approved for the treatment of
BRAF-mutant melanoma patients [6]. Dabrafenib has
since also been approved as the second BRAF inhibitor
to achieve FDA approval for the treatment of advanced
melanoma [147]. Although response rates with vemura-
fenib in patients with V600E BRAF-mutated melanoma
have been impressive, this inhibitor is associated with a
PFS of only 5-7 months, likely due to the development
of compensatory mechanisms of resistance described
below [148,149].
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proved by the FDA for advanced melanoma, after show-
ing increased survival compared to chemotherapy in a
phase III trial [150]. In addition, MEK inhibitors have
shown efficacy in those patients progressing on BRAF
inhibitors [151]. Critically, BRAF and MEK inhibitors
may have better results when given concomitantly rather
than sequentially, with concurrent treatment associated
with increased antitumor responses to therapy and a re-
duction in the severity of toxicities observed [150,151].
Different phase III trials exploring this combination are
ongoing (NCT01689519; NCT01597908; NCT01584648).
Multiple resistance mechanisms have been identified
with these drugs, including those secondary to the re-
activation of the MAPK pathway (e.g. BRAF amplifica-
tion or mutations, truncations in the BRAF protein, or
secondary mutations in NRAS and MEK), as well as acti-
vation of other pathways, such as the PI3K-AKT-mTOR
and VEGF signaling pathways [148,149,152-154]. Mul-
tiple combination regimens, based on preclinical data,
are now planned or ongoing, such as the combination of
BRAF inhibitors with VEGF inhibitors (NCT01495988).
Other small molecule inhibitors
Imatinib, a 2-phenyl amino pyrimidine derivative, is a
tyrosine kinase inhibitor with selectivity against c-KIT,
ABL, BCR-Abl, and PDGFR-α. It was coined the “magic
bullet” in 2001 when it became the first example of a
biomarker-guided therapy that revolutionized the treat-
ment of chronic myeloid leukemia (CML). It was also
subsequently approved by the FDA for the first-line
treatment of GIST [87].
Despite its clinicopathologic heterogeneity, GIST com-
monly shares similar oncogenic mutations that involve
KIT or PDGFR [155,156]. Clinical trials have demon-
strated benefit with imatinib in unresectable or meta-
static GIST [157-161], and also in the adjuvant setting
for resectable primary tumours [162,163]. Mutational
analysis has a key role in this disease, both to confirm
the initial diagnosis, and for the characterization of prog-
nostic and response biomarkers for the administration of
molecularly targeted therapies [164]. For example, GIST
responds better to imatinib therapy if it harbours a mu-
tation in exon 11, versus tumors with mutations in exon
9 or without any mutations detected [164-166]. In
addition, the PDGFR-α D842V mutation appears to
confer imatinib resistance [166]. Interestingly, while the
appearance of certain secondary mutations may be as-
sociated with imatinib resistance, they may remain sensi-
tive to other tyrosine kinase inhibitors such as sunitinib,
masitinib, nilotinib or dasatinib therapy. For example,
imatinib-resistant tumors with a KIT mutation in exon 9
still respond to sunitinib, which was FDA-approved for
second-line treatment of advanced GIST in 2006 [167].The inhibition of KIT activity with sunitinib treatment has
also been investigated in GIST [168]. Improved clinical
benefit and survival were demonstrated with primary KIT
wildtype, and KIT exon 9 mutations versus KIT exon 11
mutations [169]. In addition, secondary KIT exon 13 and
14 mutations have been associated with better survival
rates compared to KIT exon 17 and 18 mutations [169].
Vismodegib is a first-in-class, small-molecule inhibitor
of SMO, a key component of the hedgehog pathway. It
was approved for the treatment of metastatic or locally
advanced basal cell carcinoma (BCC) not suitable for
local salvage therapies. The ERIVANCE phase II trial
showed promising signs of efficacy with a response rate
of 30-43% and a 7.6-month median duration of re-
sponse [170-172]. This is an encouraging example of a
rationally-driven study based on the dysregulation of
the hedgehog signaling pathway in BCC leading to antitu-
mor activity. In addition, vismodegib has demonstrated
patient benefit in those with basal cell nevus syndrome
involving germline PTCH1 alterations [173,174]. There
are currently ongoing studies which are exploring new
schedules of vismodegib to minimize drug toxicities,
and other trials assessing the activity of vismodegib in
the adjuvant setting (NCT01815840, NCT01631331,
NCT01898598) [175].
Immunotherapies
In recent years, the field of tumor immunotherapy has
taken center stage in oncology drug development. Notable
clinical successes include the CTLA-4 inhibitor ipilimu-
mab for melanoma and PD-1/PDL-1 inhibitors [176,177].
Ipilimumab is an IgG1 monoclonal antibody against the
extracellular domain of CTLA-4, which consequently
leads to the inhibition of an early point in T-cell activa-
tion. In late phase trials, ipilimumab has demonstrated an-
titumor activity in patients with advanced melanoma
[178,179]. For example, in a randomized first-line phase
III trial that enrolled patients with advanced melanoma,
the dacarbazine plus ipilimumab combination prolonged
overall survival compared to dacarbazine plus placebo.
The combination arm was however also associated with a
high frequency of Grade 3-4 adverse events [178].
More recently, the clinical development of anti-
bodies against PD-1, such as nivolumab and lambroli-
zumab (MK3475), as well as PDL-1 inhibitors, such as
MDX-1107 or MPDL-3280, have produced impressive
antitumor responses, up to 50% [180,181]. In melanoma
patients, it also has a more favorable drug-toxicity profile
compared to ipilimumab [179,182-184]. There appear to
be complementary mechanisms of action for ipilimumab
and the anti–PD-1/anti-PDL-1 antagonists, with recent
clinical studies demonstrating that the two agents in com-
bination have an impressive additive activity in patients
with advanced melanoma [185]. Kefford and colleagues
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mas were significantly more likely to respond to MK3475
(51%) than PDL1-negative tumors (6%) (p = 0.0012).
These patients also had improved progression free survival
(12 vs 3 months respectively; p = 0.0004) [181]. Although
a similar pattern has been found in lung cancer patients
[186], this did not reach statistical significance, and PDL-1
testing is being further evaluated in a number of other
cancers [187-191]. Interestingly, some PDL-1-negative tu-
mors also respond, underlining the need for more sensi-
tive biomarkers [181].
Conclusions
The face of oncology is rapidly changing, with the in-
creased use of genetic profiling for the identification of
critical targets involved in the hallmarks of cancer. The
development of novel therapeutics, particularly those
targeting key molecular pathways, will require systematic
and rational planning to minimize the treatment of pa-
tients with ineffective and potentially toxic drugs. How-
ever, the current paradigm of drug development is also
economically unsustainable, due to the ever-escalating
costs associated with drug attrition from preclinical to
clinical studies and large one-size-fits-all phase III trials.
We believe that analytically validated and clinically quali-
fied predictive biomarkers of response hold the promise
to curbing these issues. We therefore suggest an in-
creased focus on the Pharmacological Audit Trail to
discover and validate such biomarkers to accelerate
drug development.
In the coming years, as critical cancer drivers are fur-
ther elucidated, we anticipate the accelerated develop-
ment of many more targeted monoclonal antibodies and
small molecule inhibitors [192,193]. Also, molecularly
targeted antibody-drug conjugates appear to be a prom-
ising method of delivering cytotoxic drugs in a targeted
manner, thereby optimizing drug exposure to cancer
cells while minimizing patient toxicity. In the future, we
anticipate that antibody therapeutics will also increas-
ingly involve modifications to the Fc domain in order to
trigger the immune system through the activation of T
cells and Fcγ-positive accessory cells (e.g. macrophages,
dendritic cells, natural killer cells). In addition, new
drug designs comprising bi-functional or tri-functional
bi-specific antibodies or attenuated single-chain antibodies
will be tested. For example, ertumaxomab, a tri-functional
bi-specific antibody that targets two different antigen
binding sites (anti-Her2 and anti-CD3) and the typical Fc
region, was tested in phase I and phase II studies and
showed clinical benefit and potent immunological re-
sponse in HER2-positive breast cancer [19]. Finally, we
anticipate that the immunotherapy drug development
field will be further expanded, including combination
therapies with molecularly targeted therapeutics.Competing interests
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